手法を比較
選択した手法を並べて確認できます。異なる行はハイライト表示されます。
| ランダム化比較試験のためのコクランのリスク・バイアス評価ツール2.0× | CONSORTチェックリスト：ランダム化比較試験の報告基準× | |
|---|---|---|
| 分野 | 研究方法論 | 研究方法論 |
| 系統 | Process / pipeline | Process / pipeline |
| 提唱年≠ | 2019 | 2010 (original 1996) |
| 提唱者≠ | Jonathan Sterne, Julian Higgins (Cochrane Collaboration) | Schulz et al. (CONSORT Group) |
| 種類≠ | Clinician-rated / Research team assessment | Trial author reporting checklist |
| 原典≠ | Sterne, J. A., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., ... & Higgins, J. P. (2019). RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ, 366, l4898. DOI ↗ | Schulz, K. F., Altman, D. G., & Moher, D. (2010). CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. The Lancet, 375(9721), 1657–1668. DOI ↗ |
| 別名 | RoB 2.0, RoB 2 | CONSORT, CONSORT 2010 |
| 関連 | 4 | 4 |
| 概要≠ | RoB 2 is the Cochrane Collaboration's updated methodology for assessing the risk of bias in randomized controlled trials (RCTs). Published in 2019, it replaced the original Cochrane RoB tool with a more structured, transparent approach using signalling questions and domain-based judgments to evaluate five critical sources of bias. | The CONSORT (Consolidated Standards of Reporting Trials) Statement is a 25-item evidence-based checklist and flow diagram developed to standardize reporting of parallel-group randomized controlled trials. First published in 1996 and updated in 2010 (CONSORT 2010), it is endorsed by over 600 journals including The Lancet, JAMA, and BMJ, and is mandatory or strongly recommended for RCT manuscript submission across clinical research. |
| ScholarGateデータセット ↗ |
|
|